D&D Pharmatech clinical 2trial secures statistical significance; shares hit the upper price limit, while InBody expects demand for body composition analysis to rise

D&D Pharmatech 5on 27 disclosed that its MASH (steatohepatitis) treatment clinical trial 2 had achieved statistical significance. After announcing the clinical trial results, the company’s shares surged and at one point hit the upper price limit. The following 5 on 28, the shares continued to post strong gains for a second consecutive day.

The release of the clinical trial results focused buying in the market, confirming related momentum across the biotech sector. The company said it made the relevant disclosure based on the statistical significance achieved in the trial. Investors traded based on the disclosure.

Meanwhile, InBody 5on 28 said it expects demand for body composition analysis to rise as the obesity management market expands. InBody explained that its body composition analysis devices and services are linked to demand for obesity management. The company shared its expectations for related business opportunities.

D&D Pharmatech’s clinical disclosure and InBody’s demand expectations were conveyed to the market through separate disclosures and announcements, respectively. The two companies’ announcements differed in timing and content, and were based on official documents and disclosures issued by each company. This article summarizes only facts made public by the companies.